Appareil pulmonaire
LUNG-ART
Phase III Study Comparing Post-Operative Conformal Radiotherapy to No Post-Operative Radiotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer and Mediastinal N2 Involvement
Paris, Saint-Cloud
SYLVIE HELFRE, PATRICIA MOISSON
Sein Métastatique
SAFIR02 Breast
Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer.
Paris, Saint-Cloud
MARIE PAULE SABLIN
Gynécologie
ASCORDIA01
ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses
Paris, Saint-Cloud
CAROLINE MALHAIRE, ROMAN ROUZIER
Sein Métastatique
BROCADE 3 (M12-914)
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Paris, Saint-Cloud
FRANCESCO RICCI, FLORENCE LEREBOURS
Sein Adjuvant
PENELOPE-B
An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease.
Paris, Saint-Cloud
PAUL-HENRI COTTU, ETIENNE BRAIN
Sein métastatique HER2+
SOPHIA (CP-MGAH22-04)
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment.
Paris, Saint-Cloud
FRANCESCO RICCI, ETIENNE BRAIN
Sein Adjuvant
MonarchE (I3Y-MC-JPCF)
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Paris, Saint-Cloud
PAUL-HENRI COTTU, PAUL-HENRI COTTU
Sein métastatique HER2+
DS8201-A-U301 (DESTINY- Breast02)
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1.
Paris, Saint-Cloud
Appareil pulmonaire
MK7902-007 (LEAP-007)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)
Paris, Saint-Cloud
Sein métastatique HER2+
DS8201-A-U302 (DESTINY-Breast03)
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Paris, Saint-Cloud